BIOMAT Database Logo BIOMAT Database Logo

[Clinical evaluation of imipenem/cilastatin sodium in infectious complications of hematological malignancies. Tohkai Research Group on Infections in Hematological Disorders]. 1990

K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
2nd Department of Internal Medicine, Meitetsu Hospital.

Imipenem/cilastatin sodium (IPM/CS), a newly developed carbapenem antibiotic, was administered to a total of 152 patients with severe infections complicating hematological disorders, of whom 138 patients are included in the present analysis of efficacy and 152 in that of safety. Most of the underlying diseases were acute leukemia (76/138), and most patients suffered from sepsis or suspicion of sepsis (84/138). Out of 138 patients in whom efficacy was evaluable, responses were excellent in 41 patients, good in 55, fair in 19, and poor in 23. The overall clinical efficacy rate was 69.6% (96/138). Prior antibiotic treatment and peripheral neutrophil count had significant effects on the clinical response. The overall eradication rate of bacteria was 76.2%. Adverse reactions were observed in 15 patients (9.9%) and abnormal laboratory test results in 19 patients (12.5%). From the above findings, IPM/CS is considered to be a useful antibiotic for the treatment of severe infections accompanying hematopoietic disorders.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Effects of ceftriaxone on severe infectious complications in hematological disorders. Tohkai Research Group on Infections in Hematological Disorders].
April 1989, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicating hematological disorders and solid tumors].
August 1991, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicated with hematological disorders and solid tumors].
December 1989, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
Imipenem-cilastatin monotherapy in severe infections accompanying hematological malignancies.
January 1991, Japanese journal of medicine,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Therapeutic effect of ceftizoxime on severe infectious complications in blood disorders. Tohkai Research Group on Infections in Hematopoietic Disorders].
December 1984, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Clinical evaluation of a combination therapy using cefmenoxime and cefsulodin on infections complicated by hematological disorders. Tohkai Research Group on Infections in Hematopoietic Disorders].
March 1986, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Clinical evaluation of intramuscular imipenem/cilastatin sodium in surgical infections].
December 1991, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Clinical evaluation of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders].
December 1990, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Clinical evaluation of imipenem/cilastatin sodium against infections in compromised children (malignancy, hematological disease, collagen disease)].
August 1992, The Japanese journal of antibiotics,
K Naito, and M Kobayashi, and M Okumura, and Y Ikeda, and Y Mitomo, and T Oguri, and M Tanaka, and K Ohara, and Y Kodera, and R Ohno
[Evaluation of imipenem/cilastatin sodium in neonatal infections].
November 1988, The Japanese journal of antibiotics,
Copied contents to your clipboard!